Pharmaceutical

Hospital PMI® at 53.3%; July 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., Aug. 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in July for the 11th consecutive…

1 year ago

Aquila Solutions Announces Solution for eCTD 4.0 Submissions

WARNER ROBINS, Ga., Aug. 7, 2024 /PRNewswire/ -- Aquila Solutions, a regulatory and pharmaceutical management consulting leader, has launched Altair, an…

1 year ago

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk…

1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during…

1 year ago

Speranza Therapeutics and CoAssist Pharmacy join the fight against the opioid crisis through patient access to non-invasive therapy

Partnership delivers innovative reimbursement options for S.T. Genesis, a medical device indicated for opioid withdrawal symptom managementBOCA RATON, Fla., Aug.…

1 year ago

Olympia Pharmaceuticals Bolsters Leadership Team with New Executive Appointments

New additions to the national leader in compounding pharmaceuticals team include CEO, senior director of regulatory affairs and director of…

1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory…

1 year ago

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baselineCNM-Au8 treated…

1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) --…

1 year ago